ID

40434

Description

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification; ODM derived from: https://clinicaltrials.gov/show/NCT02468661

Link

https://clinicaltrials.gov/show/NCT02468661

Keywords

  1. 1/17/19 1/17/19 -
  2. 4/20/20 4/20/20 -
  3. 4/25/20 4/25/20 -
Copyright Holder

Novartis Pharmaceuticals

Uploaded on

April 20, 2020

DOI

To request one please log in.

License

Creative Commons BY-NC 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-Small Cell Lung Cancer NCT02468661

Eligibility Non-Small Cell Lung Cancer NCT02468661

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
locally advanced or metastatic nsclc
Description

NSCLC Locally advanced malignant neoplasm | NSCLC Neoplasm metastasis

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0677984
UMLS CUI [2,1]
C0007131
UMLS CUI [2,2]
C0027627
egfr mutation (l858r and /or ex19del)
Description

EGFR mutation | EGFR Exon 19 Deletion Mutation | EGFR L858R mutation

Data type

boolean

Alias
UMLS CUI [1]
C3266992
UMLS CUI [2]
C3274204
UMLS CUI [3]
C4289657
cmet amplification by fish (gcn ≥ 6),
Description

C-MET gene amplification FISH | c-met gene Copy number

Data type

boolean

Alias
UMLS CUI [1,1]
C1711106
UMLS CUI [1,2]
C0162789
UMLS CUI [2,1]
C0072453
UMLS CUI [2,2]
C1707513
acquired resistance to egfr tki (1st or 2nd génération)
Description

Resistance Acquired EGFR TKI Generation

Data type

boolean

Alias
UMLS CUI [1,1]
C1443775
UMLS CUI [1,2]
C0439661
UMLS CUI [1,3]
C0079411
ecog performance status (ps) ≤ 1.
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with 3rd generation tki
Description

EGFR-TKI Generation Third Prior treatment

Data type

boolean

Alias
UMLS CUI [1,1]
C1443775
UMLS CUI [1,2]
C0079411
UMLS CUI [1,3]
C0205437
UMLS CUI [1,4]
C1514463
phaseii : prior treatment with any of the following agents:
Description

Phase II clinical trials | Prior treatment with following agents

Data type

boolean

Alias
UMLS CUI [1]
C0282460
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1514463
UMLS CUI [2,3]
C0332282
crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.
Description

Crizotinib | Inhibitor c-met | Inhibitor HGF targeted therapy

Data type

boolean

Alias
UMLS CUI [1]
C2974289
UMLS CUI [2,1]
C1999216
UMLS CUI [2,2]
C0072453
UMLS CUI [3,1]
C1999216
UMLS CUI [3,2]
C0062534
UMLS CUI [3,3]
C2985566
concomitant egfr tki and platinum based chemotherapy as first line regimen.
Description

Concomitant therapy EGFR-TKI | Concomitant therapy Platinum-based Chemotherapy regimen | First line treatment

Data type

boolean

Alias
UMLS CUI [1,1]
C1707479
UMLS CUI [1,2]
C1443775
UMLS CUI [2,1]
C1707479
UMLS CUI [2,2]
C1514162
UMLS CUI [2,3]
C0392920
UMLS CUI [3]
C1708063
platinum-based chemotherapy as first line treatment
Description

First line Chemotherapy Platinum-Based

Data type

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C0392920
UMLS CUI [1,3]
C1514162

Similar models

Eligibility Non-Small Cell Lung Cancer NCT02468661

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
NSCLC Locally advanced malignant neoplasm | NSCLC Neoplasm metastasis
Item
locally advanced or metastatic nsclc
boolean
C0007131 (UMLS CUI [1,1])
C0677984 (UMLS CUI [1,2])
C0007131 (UMLS CUI [2,1])
C0027627 (UMLS CUI [2,2])
EGFR mutation | EGFR Exon 19 Deletion Mutation | EGFR L858R mutation
Item
egfr mutation (l858r and /or ex19del)
boolean
C3266992 (UMLS CUI [1])
C3274204 (UMLS CUI [2])
C4289657 (UMLS CUI [3])
C-MET gene amplification FISH | c-met gene Copy number
Item
cmet amplification by fish (gcn ≥ 6),
boolean
C1711106 (UMLS CUI [1,1])
C0162789 (UMLS CUI [1,2])
C0072453 (UMLS CUI [2,1])
C1707513 (UMLS CUI [2,2])
Resistance Acquired EGFR TKI Generation
Item
acquired resistance to egfr tki (1st or 2nd génération)
boolean
C1443775 (UMLS CUI [1,1])
C0439661 (UMLS CUI [1,2])
C0079411 (UMLS CUI [1,3])
ECOG performance status
Item
ecog performance status (ps) ≤ 1.
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
EGFR-TKI Generation Third Prior treatment
Item
prior treatment with 3rd generation tki
boolean
C1443775 (UMLS CUI [1,1])
C0079411 (UMLS CUI [1,2])
C0205437 (UMLS CUI [1,3])
C1514463 (UMLS CUI [1,4])
Phase II clinical trials | Prior treatment with following agents
Item
phaseii : prior treatment with any of the following agents:
boolean
C0282460 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C0332282 (UMLS CUI [2,3])
Crizotinib | Inhibitor c-met | Inhibitor HGF targeted therapy
Item
crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.
boolean
C2974289 (UMLS CUI [1])
C1999216 (UMLS CUI [2,1])
C0072453 (UMLS CUI [2,2])
C1999216 (UMLS CUI [3,1])
C0062534 (UMLS CUI [3,2])
C2985566 (UMLS CUI [3,3])
Concomitant therapy EGFR-TKI | Concomitant therapy Platinum-based Chemotherapy regimen | First line treatment
Item
concomitant egfr tki and platinum based chemotherapy as first line regimen.
boolean
C1707479 (UMLS CUI [1,1])
C1443775 (UMLS CUI [1,2])
C1707479 (UMLS CUI [2,1])
C1514162 (UMLS CUI [2,2])
C0392920 (UMLS CUI [2,3])
C1708063 (UMLS CUI [3])
First line Chemotherapy Platinum-Based
Item
platinum-based chemotherapy as first line treatment
boolean
C1708063 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C1514162 (UMLS CUI [1,3])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial